PamGene technology involved in lecture and poster on ESMO Stockholm
During the 2011 ESMO in Stockholm, two scientist reported on their development in the use of the PamGene technology. Kathrine Re gave a lecture titled Protein Kinase Activity and Therapy Response. Dr Koh presented a poster on his study of the identification of biomarkers to predict drug response in scirrhous gastric cancer cell lines. For both studies, tyrosine kinase activity profiling with PamChip microarrays was used.


Lecture of Kathrine Roe

Kathrine Røe is a scientist at the Institute for Cancer Research of  The Norwegian Radium Hospital in Oslo, Norway. She presented examples of two studies performed by using PamChip Arrays. The central question in these studies was whether functional biomarkers of disease aggressiveness and therapy response could be identified. She concludes that further individualized cancer therapy may benefit from novel analytic technologies like PamGene’s.

Kathrine Røe: ‘The lecture was scheduled during the Scientific Symposium Novel Oncoproteomic Technology, which was a new subject on this congress. Our institute got an invitation, apparently someone knew that we’re working on new approaches. The attendants were quite surprised that the method I presented could work in clinical settings as well. It was an honour to give the lecture, because I’m still a PhD-student and I’ll finish my thesis in November.’

Read the abstract of the lecture

Dr Koh’s poster
Dr Koh is Chief of the Drug Discovery and Development Division at the Shizuoka Cancer Center Research Institute in Shizuoka in Japan. His study concerns scirrhous cancer, which accounts for  approximately 10% of all gastric cancers. Its proliferation is driven by several growth factors. Standard chemotherapy is currently not satisfactory. Recently, chemotherapy combined with a multi-targeted kinase inhibitor, such as sunitinib, has been reported to be effective in a subset of patients with this type of cancer. But no predictive biomarker or companion diagnostics has yet been developed.
Dr Koh concludes that an in vitro assay on PamChip® microarrays could serve as a companion diagnostic test for multi-targeted kinase inhibitors in order to predict responses in patients with scirrhous gastric cancer.
Read the abstract